07:58 AM EDT, 10/18/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion and recommended approval of Alhemo to treat adults with hemophilia, based on data from the phase 3 explorer7 study,

The company expects final approval by the European Commission within roughly two months.

Price: 117.25, Change: -0.97, Percent Change: -0.82